QS-21 |
رقم الكتالوجGC63377
One-Click Copy Product Info
|
يمكن استخدام QS-21 ، وهو صابونيمنشط للجهاز المناعي ، كإضافة فعالة لقاح.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 141256-04-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
QS-21 is an immune-stimulatory saponin that can be used as an effective vaccine adjuvant[1]. QS-21 enhances vaccine immune responses by activating dendritic cells and helper T cells, promoting antibody production and cell-mediated immune responses[2]. QS-21 is an activator of the NLRP3 inflammasome and leads to subsequent release of caspase-1-dependent pro-inflammatory cytokines IL-1β and IL-18[3].
In vitro, QS-21 (2.5, 5, 25 μM) treatment of HUVEC and PBMC cells for 24 hours significantly reduced cell viability, with this cytotoxic effect being more pronounced in HUVEC cells[4]. QS-21 (0-50 μM) treatment of two human gastric cancer cell lines (SNU 1 and KATO III) and a normal human cell line (GES-1) for 24 hours resulted in dose-dependent toxicity in KATO III and SNU 1 cells, with IC50 values of 67μM and 13.6μM, respectively, but showed almost no cytotoxicity to GES-1 cells[5].
In vivo, immunization of mice with Aβ42 formulated with QS-21 adjuvant produced the highest antibody titers, followed by CFA/IFA > alum > TMG[6].
References:
[1] Marty-Roix R, Vladimer G I, Pouliot K, et al. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants[J]. Journal of Biological Chemistry, 2016, 291(3): 1123-1136.
[2] Welsby I, Detienne S, N’Kuli F, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21[J]. Frontiers in immunology, 2017, 7: 663.
[3] Lacaille-Dubois M A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review[J]. Phytomedicine, 2019, 60: 152905.
[4] Campos-Estrada C, Riquelme B, Vergara M, et al. In vitro Notch-mediated adjuvant immunogenic potency is induced by combining QS-21 and MPL in a co-culture model of PBMC and HUVEC cells[J]. Toxicology in Vitro, 2020, 68: 104947.
[5] Guzmán L, Villalón K, Marchant M J, et al. In vitro evaluation and molecular docking of QS-21 and quillaic acid from Quillaja saponaria Molina as gastric cancer agents[J]. Scientific Reports, 2020, 10(1): 10534.
Cribbs D H, Ghochikyan A, Vasilevko V, et al. Adjuvant‐dependent modulation of Th1 and Th2 responses to immunization with β‐amyloid[J]. International immunology, 2003, 15(4): 505-514.
| Cas No. | 141256-04-4 | SDF | |
| Formula | C92H148O46 | M.Wt | 1990.13 |
| الذوبان | DMSO : 100 mg/mL (50.25 mM; Need ultrasonic); H2O : 50 mg/mL (25.12 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 502.5 μL | 2.5124 mL | 5.0248 mL |
| 5 mM | 100.5 μL | 502.5 μL | 1.005 mL |
| 10 mM | 50.2 μL | 251.2 μL | 502.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)